Matinas BioPharma Holdings, Inc.
MTNB
$0.59
-$0.05-7.84%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 85.00K | 2.46M | 4.70M | 8.07M | 11.43M |
| Gross Profit | -85.00K | -2.46M | -4.70M | -8.07M | -11.43M |
| SG&A Expenses | 6.88M | 6.94M | 7.50M | 8.13M | 8.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.96M | 9.40M | 12.20M | 16.20M | 20.16M |
| Operating Income | -6.96M | -9.40M | -12.20M | -16.20M | -20.16M |
| Income Before Tax | -10.35M | -16.95M | -19.69M | -20.16M | -24.33M |
| Income Tax Expenses | -- | -80.00K | -80.00K | -80.00K | -80.00K |
| Earnings from Continuing Operations | -10.35 | -16.87 | -19.61 | -20.08 | -24.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.35M | -16.87M | -19.61M | -20.08M | -24.25M |
| EBIT | -6.96M | -9.40M | -12.20M | -16.20M | -20.16M |
| EBITDA | -6.92M | -9.28M | -11.99M | -15.91M | -19.79M |
| EPS Basic | -2.06 | -3.41 | -3.86 | -3.98 | -4.99 |
| Normalized Basic EPS | -0.83 | -1.15 | -1.50 | -1.99 | -2.59 |
| EPS Diluted | -2.06 | -3.41 | -3.86 | -3.98 | -4.99 |
| Normalized Diluted EPS | -0.83 | -1.15 | -1.50 | -1.99 | -2.59 |
| Average Basic Shares Outstanding | 21.89M | 20.70M | 20.30M | 20.20M | 19.46M |
| Average Diluted Shares Outstanding | 21.89M | 20.70M | 20.30M | 20.20M | 19.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |